Validated KM-12 Xenograft Model:
Subcutaneous Xenograft Tumor Model

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

Advancing Xenograft Models in Colorectal Cancer Research

Colorectal cancer is a major global health burden marked by high molecular heterogeneity and poor outcomes in advanced stages, despite progress in therapeutics. Xenograft models, in which human tumor cells are implanted into immunodeficient mice, have become indispensable in preclinical research, offering platforms to evaluate tumor growth, drug efficacy, and mechanisms of resistance *in vivo*. While traditional subcutaneous xenografts facilitate high-throughput drug testing, they often fall short in recapitulating the complex tumor microenvironment. Recent advances in orthotopic and patient-derived xenograft systems have improved biological relevance, yet challenges persist in modeling stromal interactions, immune dynamics, and metastatic behavior. This research aims to enhance the utility of colon cancer xenograft models by incorporating microenvironmental context and testing combination therapies targeting both tumor-intrinsic and extrinsic pathways. The goal is to uncover mechanisms of resistance and identify new therapeutic targets, thereby advancing personalized treatment strategies in colorectal cancer.

KM-12 Cell Line

The KM-12 cell line, derived from a human colorectal adenocarcinoma, has emerged as a pivotal model in cancer research due to its BRAF V600E mutation and KRAS wild-type genotype. This molecular profile renders KM-12 particularly relevant for investigating the efficacy and resistance mechanisms of targeted therapies involving the MAPK signaling cascade, such as BRAF and MEK inhibitors. Numerous studies have demonstrated that KM-12 cells exhibit constitutive activation of ERK signaling, which contributes to their oncogenic phenotype and intrinsic resistance to EGFR-targeted agents. Proteomic and transcriptomic analyses have revealed aberrations in cell migration, epithelial-mesenchymal transition, and PI3K/AKT signaling, highlighting their utility in studying metastatic behavior. KM-12 has also been extensively used in subcutaneous xenograft models and high-throughput drug screening to evaluate synthetic lethality in BRAF-mutant colorectal cancers. However, despite its widespread application, the model remains underexplored in 3D organoid systems and orthotopic implantation settings. Furthermore, the role of the tumor microenvironment, including stromal and immune components, in modulating therapeutic responses in KM-12 cells is insufficiently characterized, presenting a critical gap in the translational relevance of this model.



Figure 1. Tumor Histology. H&E stained section of a subcutaneously-implanted KM-12 tumor (Altogen Labs).

Altogen Labs Validated KM-12 Xenograft Model

Altogen Labs offers a comprehensive suite of preclinical research services designed to support oncology drug development and molecular biology studies. These services include pharmacology and toxicology testing, IC50 determination across over 100 cancer cell lines, and anti-tumor activity evaluation using more than 80 validated xenograft models. Specialized capabilities include liposome-based encapsulation for siRNA, mRNA, and DNA delivery, ELISA and cell-based assay development, and generation of stable cell lines within 28 days, including RNAi-modified lines for long-term gene silencing.



Figure 2. Tumor growth curve for KM-12 xenograft-bearing mice treated with buffer (control) or entrectinib (100 mg/kg). Data show mean values ± SEM (Altogen Labs).

Additional biology CRO services feature GLP-compliant *in vivo* toxicology studies in mouse and rat models, LD50 assessments, teratoma analysis, and advanced RNA interference platforms. Altogen Labs also provides cell banking and cryopreservation services and supports an extensive catalog of xenograft models, including brain, lung, breast, pancreatic, prostate, ovarian, gastric, colon, and melanoma cancer types. Among these, the KM-12 xenograft model is prominently featured and is available for both monotherapy and combination therapy studies. The KM-12 cell line, derived from a human colorectal carcinoma classified as Dukes B2, presents a valuable model for preclinical research, especially due to its low metastatic potential and molecular profile including TPM3-NTRK1 fusion and BRAF mutation. Several studies have leveraged the KM-12 model to explore targeted therapy strategies. Kita et al. (2017) demonstrated that KM-12 cells were highly responsive to entrectinib and crizotinib, TRK-A inhibitors, and used this model to assess brain metastasis-targeting agents. Prewett et al. (2007) used KM-12 xenografts to investigate the synergistic effects of cetuximab and oxaliplatin, finding reduced expression of XRCC1 and increased platinum-DNA adduct accumulation, suggesting a mechanism to overcome drug resistance. Ardini et al. (2014) identified the TRKA inhibitor NMS-P626 as highly effective against the TPM3-NTRK1 fusion present in KM-12 cells. The standard KM-12 xenograft study involves subcutaneous injection of 1×10^6 cells mixed with Matrigel into immunodeficient mice, followed by tumor volume monitoring and treatment group randomization upon tumor establishment. Endpoints include tumor size, weight, and molecular analysis of harvested tissues. These models provide critical data for evaluating novel therapeutics, supporting regulatory submissions, and advancing personalized medicine approaches in colorectal cancer research.



Figure 3. Mean tumor weight of KM-12 xenografts in untreated control mice versus mice treated with entrectinib (100 mg/kg, twice daily for 10 days). Entrectinib treatment resulted in a marked reduction in tumor burden by the end of the study. Error bars represent standard deviation (Altogen Labs).

KM-12 Subcutaneous Xenografts in Colorectal Cancer Research

Subcutaneous xenograft transplantation represents a foundational technique in preclinical oncology, offering a standardized and accessible platform for assessing tumor growth and therapeutic response. The KM-12 cell line, a BRAF V600E-mutant colorectal adenocarcinoma model, has been widely utilized in such systems due to its reliable tumorigenicity and well-characterized molecular profile. When implanted into the flanks of immunodeficient mice, KM-12 cells consistently form tumors within a few weeks, allowing for reproducible evaluation of drug efficacy. These models have been instrumental in characterizing the effects of MAPK pathway inhibitors and elucidating mechanisms of adaptive resistance, particularly through upregulation of PI3K/AKT and RTK-mediated signaling pathways.

Further research using KM-12 xenografts has demonstrated the therapeutic benefit of combinatorial approaches, such as co-inhibition of BRAF with PI3K or EGFR, which have produced superior antitumor effects compared to monotherapy. These studies have also enabled the identification of pharmacodynamic biomarkers like phosphorylated ERK and AKT to monitor treatment response. However, the subcutaneous model lacks the anatomical and microenvironmental fidelity of orthotopic systems, limiting its capacity to fully replicate tumor-stroma and immune interactions. Despite this, KM-12 subcutaneous xenografts remain powerful for mechanistic exploration and drug screening. Future advancements incorporating elements of the tumor microenvironment or humanized immune systems may enhance their translational relevance and broaden their applicability in modeling resistance and therapeutic outcomes.

Case Study: Preclinical Efficacy of Merestinib in TPM3-NTRK1 Fusion-Positive Colorectal Cancer

In a study published by Konicek et al. in *Oncotarget* journal, the authors evaluated the preclinical efficacy of the multi-kinase inhibitor merestinib (LY2801653) in NTRK fusion-positive cancers, using the KM-12 colorectal carcinoma model as a central platform. Merestinib, an orally bioavailable type II inhibitor of MET, AXL, MKNK1/2, and NTRK1/2/3, showed potent inhibition of NTRK1 phosphorylation in KM-12 cells harboring a TPM3-NTRK1 fusion, with complete suppression of p-NTRK1 (Y490) at 62.5 nM. This translated to strong antiproliferative activity in both two-dimensional and three-dimensional cultures, with IC50 values of 10 nM and 45 nM respectively. *In vivo*, merestinib induced near-complete tumor regression in KM-12 xenografts and a patient-derived xenograft (EL1989) bearing the same fusion.

The latter model showed a 39 percent reduction in tumor volume and a 63 percent decrease in Ki-67 staining, indicating substantial antiproliferative effects. Histological analysis revealed reduced tumor cell viability and notable mucin accumulation, potentially indicative of stromal or differentiation changes. To explore resistance mechanisms, the study utilized NIH-3T3 cells engineered to express TPM3-NTRK1 with G595R or G667C mutations. Merestinib retained efficacy against G667C-expressing tumors, producing sustained regression *in vivo*, while entrectinib showed only a transient response. Neither compound was effective against G595R-mutant tumors. X-ray crystallography confirmed that merestinib binds the NTRK1 kinase domain in a DFG-out conformation, avoiding steric interference from resistance-associated residues. These structural insights support merestinib's activity in the setting of certain acquired mutations that confer resistance to type I inhibitors. While additional targets such as MKNK1/2 and their downstream effects on eIF4E phosphorylation may also contribute to antitumor activity, the study's focus on KM-12 highlights merestinib as a promising therapeutic candidate for NTRK-driven malignancies, particularly those resistant to currently available NTRK inhibitors. Further clinical investigation is warranted.

Additional Case Study: AZD4547 Targets TPM3-NTRK1 in KM12 Xenografts With Antitumor Efficacy

In a study published by Cho et al. in *Frontiers in Oncology* journal, the authors assessed the preclinical efficacy of AZD4547, a selective FGFR1-3 inhibitor, in NTRK1 fusion-positive cancers using KM12(Luc) xenograft models as a central platform. Originally developed to target FGFR-driven malignancies, AZD4547 demonstrated unexpected potency against the TPM3-NTRK1 fusion present in KM12(Luc) cells. *In vitro* assays revealed that AZD4547 inhibited TRKA/B/C with low nanomolar potency and effectively suppressed TRKA phosphorylation, downstream PLC-γ and AKT signaling, and MAPK target gene expression. Treatment with AZD4547 induced G0/G1 cell cycle arrest, reduced CCND1 and E2F1 expression, and increased apoptosis in KM12(Luc), as confirmed by cleaved PARP1 expression and annexin V staining. Anchorage-independent growth was abolished following 14 days of AZD4547 exposure, with colony formation completely suppressed.

In vivo, oral administration of AZD4547 at 40 mg/kg significantly delayed tumor growth in athymic nude mice bearing KM12(Luc) xenografts, with no associated loss in body weight. Tumor tissue analysis demonstrated reduced TRKA phosphorylation, confirming on-target activity. While AZD4547 displayed comparable antiproliferative potency to approved TRK inhibitors such as LOXO101 and LOXO195 in wild-type TRKA-expressing models, it lacked efficacy against Ba/F3 cells expressing clinically relevant resistance mutations such as G595R and G667C. These data highlight AZD4547's potential as a repositioned TRK inhibitor, particularly in fusion-driven colorectal cancers exemplified by the KM12 model. The study's use of well-characterized xenografts, pharmacodynamic biomarker validation, and cross-comparison with established TRK inhibitors enhances its translational relevance. Future studies are warranted to optimize AZD4547's structural features to overcome acquired resistance and to explore its integration into combinatorial therapeutic strategies.

Targeting the Mevalonate Pathway to Overcome KM12 Drug Resistance

Resistance to tyrosine kinase inhibitors in NTRK fusion-positive colorectal cancer is increasingly attributed to non-genomic mechanisms, particularly metabolic reprogramming. In KM12 colon cancer cells, which harbor a TPM3-NTRK1 rearrangement, resistance to multiple TRK inhibitors is consistently associated with overexpression of HMGCS2, an enzyme that regulates ketogenesis and feeds into the mevalonate pathway. This upregulation occurs regardless of the phosphorylation status of TRK or the activation state of downstream MAPK components, implicating a TRK-independent mechanism of resistance. Functional knockdown of HMGCS2 restores sensitivity to TRK inhibitors, induces apoptotic signaling, and suppresses proliferation in resistant KM12 sublines. These effects are reversed by supplementation with mevalonolactone, confirming the central role of the mevalonate pathway. Furthermore, pharmacologic agents such as simvastatin and silibinin effectively potentiate TRK inhibitor activity by suppressing HMGCS2 expression or function, with synergistic antitumor effects observed *in vitro* and in xenograft models.

These results position HMGCS2 as a key metabolic driver of therapeutic resistance and underscore the broader relevance of lipid biosynthetic pathways in colon cancer progression. Unlike resistance mechanisms involving secondary kinase domain mutations or reactivation of canonical MAPK signaling, HMGCS2-mediated resistance operates independently of AKT and ERK, revealing an alternative survival axis through cholesterol synthesis and small GTPase activation. The delayed resistance observed with statin co-treatment suggests a practical approach for extending the efficacy of TRK-targeted therapies in NTRK-driven tumors. Given the clinical accessibility of statins and the mechanistic clarity provided by these findings, further exploration in immune-competent and orthotopic KM12 models is warranted. Targeting the metabolic landscape of cancer cells offers a compelling strategy to overcome drug tolerance and improve therapeutic durability in molecularly defined colorectal cancers.

Next-Generation TRK Therapy Shows Potency in KM12 Xenografts

Zurletrectinib is a next-generation TRK inhibitor that exhibits enhanced potency and intracranial activity against NTRK fusion-positive cancers, including colorectal cancer driven by the TPM3-NTRK1 fusion present in the KM12 cell line. In both biochemical and cellular models, zurletrectinib displayed low-nanomolar IC50 values against TRKA, TRKB, and TRKC kinases, and significantly inhibited proliferation in KM12 cells. Compared to first-generation inhibitors like larotrectinib, zurletrectinib was effective at doses up to 30-fold lower in *in vivo* xenograft models. Notably, this compound retained efficacy against several known TRK resistance mutations, including the solvent-front G595R and the xDFG G667A substitutions. However, its activity diminished against the G667C mutant, which creates steric hindrance due to cysteine bulk.

In xenograft models derived from KM12 cells, zurletrectinib achieved tumor regression with minimal toxicity at low oral doses. Pharmacokinetic profiling in rats revealed that it had superior brain penetration relative to selitrectinib and repotrectinib, a feature further validated in intracranial glioma models bearing TRK resistance mutations. Mice implanted with resistant tumors and treated with zurletrectinib exhibited significantly prolonged survival compared to other treatment arms. These patterns confirm the drug's enhanced bioavailability, robust target engagement, and improved therapeutic profile in both extracranial and intracranial settings. The methodology, incorporating kinase assays, *in vivo* modeling, and molecular docking, provides a rigorous preclinical framework. Despite the absence of orthotopic KM12 models or immunocompetent systems, these results position zurletrectinib as a leading candidate for overcoming on-target resistance in TRK fusion-driven tumors, particularly when central nervous system involvement is a concern. Further clinical investigation in KM12-relevant disease contexts is warranted.

Imaging TrkA Activity in KM-12 Colorectal Cancer

KM-12 is a human colorectal cancer cell line driven by a TPM3-NTRK1 gene fusion, which leads to constitutive activation of the TrkA receptor tyrosine kinase. This oncogenic alteration makes KM-12 an important model for evaluating targeted therapies and imaging strategies that focus on Trk fusion proteins. *In vitro* studies using the fluorine-18-labeled PET tracer \[18F]TRACK demonstrated time-dependent uptake in KM-12 cells, peaking at over 200 percent radioactivity per milligram of protein within 60 minutes. Blocking experiments with entrectinib and non-radioactive TRACK confirmed high-affinity binding to TrkA, as both compounds produced similar low-nanomolar IC50 values. *In vivo* imaging in KM-12 xenograft-bearing mice showed selective tracer accumulation in tumor tissue, with tumor-to-muscle ratios increasing over time. However, absolute tumor uptake remained modest, which may reflect either limited expression or reduced accessibility of the intracellular kinase domain *in vivo*.

Further receptor profiling through immunohistochemistry and western blotting revealed relatively low TrkA expression in KM-12 tumor tissue compared to high TrkB levels in brown adipose tissue, where \[18F]TRACK uptake was significantly higher. Pharmacologic activation of TrkA using amitriptyline increased \[18F]TRACK retention in KM-12 tumors, confirming the tracer's sensitivity to receptor activation status. Co-treatment with entrectinib reversed this effect, indicating specific target engagement. These findings validate KM-12 as a functionally informative model for testing radiolabeled Trk inhibitors and support the clinical utility of \[18F]TRACK in identifying Trk-expressing tumors. Future studies should focus on using orthotopic or metastatic KM-12 models and improving detection of fusion proteins to optimize noninvasive imaging strategies for NTRK-driven cancers.

Xenograft animal models are essential in the preclinical evaluation of anti-cancer therapeutics by enabling *in vivo* assessment of drug efficacy against specific tumor types. These studies involve the engraftment of tumorigenic cell lines into immunocompromised mice or rats, either subcutaneously or orthotopically, followed by monitoring of tumor growth and response to treatment. All clinically approved oncology drugs have undergone evaluation using such models, which are highly intricate and require careful consideration of the animal strain, cell line characteristics, administration route, dosing schedule, and detailed analyses including tumor growth kinetics, histopathology, and molecular profiling of mRNA and protein expression. Altogen Labs supports this critical phase of drug development by offering over 90 standardized Cell Line Derived Xenograft (CDX) models and more than 30 Patient Derived Xenograft (PDX) models. Additional services include the generation of stable cell lines with long-term gene silencing or protein overexpression, as well as gene and protein expression analysis using RT-PCR and the ProteinSimple WES system.

All *in vivo* studies at Altogen Labs are conducted in accordance with IACUC regulations and are fully GLP-compliant. Mice are acclimatized, sorted by body mass, and monitored daily for tumor progression and clinical indicators. Clients receive detailed reports covering methodology, raw data, statistical analyses, and interpretative results. For the KM-12 xenograft model specifically, available study options include tumor growth delay (TGD), tumor growth inhibition (TGI), various administration routes (including intravenous, intratracheal, intraperitoneal, intratumoral, oral gavage, and micro-injection), and orthotopic or metastatic engraftment strategies. Additional services include immunohistochemistry, blood chemistry, histopathology, toxicity assessment, survival analysis, and optional positive control groups using cyclophosphamide (50 mg/kg, intramuscular injection). These capabilities allow for tailored experimental designs that support rigorous evaluation of investigational compounds in TPM3-NTRK1-driven colorectal cancer models such as KM-12.



Figure 4. Overview of *in vivo* pharmacology and toxicology services offered by Altogen Labs, including dose-response analysis, toxicological profiling, and evaluation of mutagenic, carcinogenic, and immunotoxic effects.

References:

Cho H, Kim N, Murakami T, Sim T. Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs. *Front Oncol.* 2021 Nov 1;11:757598. doi: 10.3389/fonc.2021.757598. PMID: 34790577; PMCID: PMC8591201.

Kato Y, Matsumoto M, Takano N, Hirao M, Matsuda K, Tozuka T, Onda N, Nakamichi S, Takeuchi S, Miyanaga A, Noro R, Gemma A, Seike M. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway. *Cancer Med.* 2024 Jun;13(12):e7393. doi: 10.1002/cam4.7393. Erratum in: Cancer Med. 2024 Dec;13(23):e70350. doi: 10.1002/cam4.70350. PMID: 38923428; PMCID: PMC11194613.

Konicek BW, Capen AR, Credille KM, Ebert PJ, Falcon BL, Heady GL, Patel BKR, Peek VL, Stephens JR, Stewart JA, Stout SL, Timm DE, Um SL, Willard MD, Wulur IH, Zeng Y, Wang Y, Walgren RA, Betty Yan SC. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. *Oncotarget*. 2018 Feb 13;9(17):13796-13806. doi: 10.18632/oncotarget.24488. PMID: 29568395; PMCID: PMC5862616.

Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. *Br J Cancer*. 2024 Aug;131(3):601-610. doi: 10.1038/s41416-024-02760-1. Epub 2024 Jun 20. PMID: 38902532; PMCID: PMC11300601.

Wuest M, Bailey JJ, Dufour J, Glubrecht D, Omana V, Johnston TH, Brotchie JM, Schirrmacher R. Toward *in vivo* proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases. *EJNMMI* Res. 2022 Jul 30;12(1):46. doi: 10.1186/s13550-022-00915-w. PMID: 35907096; PMCID: PMC9339071.

Keywords: KM-12, colon cancer, xenograft, *in vivo*, cancer, preclinical, research, *in vivo* pharmacology, colon, colorectal, PDX, CDX